Found 1 Presentation For Request "825P"
825P - Olaparib maintenance therapy in routine clinical practice: Quality of life interim results of the non-interventional C-PATROL study in ovarian cancer patients in Germany
- Frederik Marmé (Mannheim, Germany)
Abstract
Background
The preservation of health-related quality of life (HRQoL) is a very important treatment goal in relapsed ovarian cancer (OC) patients during maintenance treatment. Olaparib hard capsules were the first poly (ADP-ribose) polymerase inhibitor approved in the EU in Dec 2014 as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed (PSR)
Methods
The German prospective non-interventional study C-PATROL (NCT02503436) collects routine clinical and patient-reported outcome (PRO) data of
Results
271
Conclusions
This analysis indicates that maintenance treatment with olaparib is well tolerated under routine conditions and had no apparent adverse impact on HRQoL. Results are in line with HRQoL results of the clinical trial program for olaparib in PSR-OC.
Clinical trial identification
NCT02503436.
Editorial acknowledgement
Medical writing assistance was provided by Dr. Yvonne Holighaus, Alcedis GmbH, Giessen, funded by AstraZeneca.
Legal entity responsible for the study
AstraZeneca, Germany.
Funding
AstraZeneca, Germany.
Disclosure
F. Marmé: Honoraria (institution), Research grant/Funding (institution): Roche/Genentech; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Tesaro; Honoraria (self), Research grant/Funding (institution): Clovis Oncology; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Eisai; Honoraria (self), Advisory/Consultancy: Celgene; Honoraria (self), Advisory/Consultancy: Genomic Health; Honoraria (self): PharmaMar; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Research grant/Funding (institution): MSD Oncology; Advisory/Consultancy, Research grant/Funding (institution): Vaccibody; Honoraria (institution), Advisory/Consultancy: Immunomedics; Honoraria (self), Advisory/Consultancy: CureVac; Honoraria (self), Advisory/Consultancy: Amgen; Honoraria (self), Advisory/Consultancy: Janssen-Cilag. F. Hilpert: Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Tesaro; Honoraria (self), Advisory/Consultancy: Clovis; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: PharmaMar; Honoraria (self): Pfizer; Honoraria (self): Novartis. J.P. Grabowski: Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: GSK-Tesaro; Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony: Clovis; Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Riemser; Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Vifor Pharma. A. El-Balat: Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: PharmaMar; Advisory/Consultancy, Speaker Bureau/Expert testimony: Olympus. A. Hartkopf: Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eisai; Advisory/Consultancy, Speaker Bureau/Expert testimony: GenomicHealth; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Tesaro; Advisory/Consultancy, Speaker Bureau/Expert testimony: Teva. R. Glowik: Full/Part-time employment: AstraZeneca. J. Sehouli: Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: PharmaMar; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Clovis; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Tesaro; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: Roche Diagnostics; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy: Merck; Advisory/Consultancy: Bayer; Advisory/Consultancy: Eisai; Research grant/Funding (institution): Bristol-Myers; Advisory/Consultancy, Research grant/Funding (institution): Lilly; Research grant/Funding (institution): MedImmune; Advisory/Consultancy: Johnson and Johnson; Advisory/Consultancy: MSD; Advisory/Consultancy: Novocure; Advisory/Consultancy: Amgen. All other authors have declared no conflicts of interest.